Intelligence · Clinical Pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs: 4,713

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

Bioprojet Pharma

narcolepsy with cataplexy, Narcolepsy

phase 1 other active

1 trial
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

Bioprojet Pharma

Narcolepsy, Narcolepsy with cataplexy

phase 1 other active

1 trial
Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

Bioprojet Pharma

Binge eating disorder

phase 1 other active

1 trial
Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

Chiesi Farmaceutici S.p.A

Chronic obstructive pulmonary disease

phase 1 other active

1 trial
Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

Lacuna Pharma Pty Ltd

not applicable (submitted trial is a bioequivalence study)

phase 1 other active

1 trial
Opicapone

NEUROCRINE BIOSCIENCES INC

Parkinson Disease

phase 1 small molecule completed

1 trial
Opioid Agonist

BRIGHT MINDS BIOSCIENCES INC.

Opioid Use

phase 1 small molecule completed

1 trial
Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

Disc Medicine

Esophageal cancer

phase 1 other active

1 trial
Oral Fosmanogepix

Basilea Pharmaceutica

Healthy

phase 1 small molecule completed

1 trial
Oral methylphenidate and Oral haloperidol

BRIGHT MINDS BIOSCIENCES INC.

Nicotine Dependence

phase 1 small molecule completed

1 trial
Original formulation EMB-001

BRIGHT MINDS BIOSCIENCES INC.

Cocaine Use Disorder

phase 1 small molecule completed

1 trial
Oshadi Oral Insulin

BRIGHT MINDS BIOSCIENCES INC.

Diabetes

phase 1 small molecule completed

1 trial
Osimertinib

PUMA BIOTECHNOLOGY, INC.

Lung Cancer Metastatic

phase 1 small molecule active

1 trial
Outpatient MST/OPTION-A

BRIGHT MINDS BIOSCIENCES INC.

Substance-Related Disorders

phase 1 other completed

1 trial
Oxcarbazepine

Teva Pharma GmbH

Healthy

phase 1 small molecule completed

2 trials
Oxcarbazepine (brand name vs generic drugs)

BRIGHT MINDS BIOSCIENCES INC.

Epilepsy

phase 1 small molecule completed

1 trial
Oxidized regenerated cellulose(ORC)

Hospital Authority, Hong Kong

Thyroidectomy

phase 1 small molecule completed

1 trial
OxyCODONE 5 mg Oral Tablet

BRIGHT MINDS BIOSCIENCES INC.

Pain

phase 1 small molecule active

1 trial
Oxycodone

BRIGHT MINDS BIOSCIENCES INC.

Opioid Use Disorder

phase 1 small molecule completed

1 trial
Oxycodone (OxyNorm®) Injection

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Pain

phase 1 small molecule completed

1 trial
Oxycodone (OxyNorm®) Injection

Mundipharma Pty Limited

Pain

phase 1 small molecule completed

1 trial
Oxycodone IN

BRIGHT MINDS BIOSCIENCES INC.

Physiologically Based Pharmacokinetic

phase 1 small molecule completed

1 trial
Oxycodone Medication First

BRIGHT MINDS BIOSCIENCES INC.

Prescription Drug Abuse (Not Dependent)

phase 1 small molecule completed

1 trial
Oxycodone Tamper Resistant

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Chronic Pain

phase 1 small molecule completed

3 trials
Oxycodone and Midazolam

BRIGHT MINDS BIOSCIENCES INC.

Hypercapnia

phase 1 small molecule completed

1 trial
Oxymetazoline

United Therapeutics Europe Ltd

Fecal Incontinence

phase 1 small molecule active

1 trial
Oxytocin

United Therapeutics Europe Ltd

Unit Cohesion

phase 1 small molecule completed

1 trial
Oxytocin

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Oxytocin Effect on Memory Performance During Phase 1

phase 1 small molecule completed

1 trial
Oxytocin lower does (24IU)

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Healthy Adult Male

phase 1 small molecule active

1 trial
Oxytocin lower dose (24IU)

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Healhty

phase 1 small molecule active

1 trial
Oxytocin nasal spray

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Healthy

phase 1 small molecule completed

1 trial
Oxytocine and migraine

Disc Medicine

This is a study in healthy volunteers. We will study the trigeminovascular system, which is relevant in the pathophysiology of migraine.

phase 1 other active

1 trial
P3C541b Lipopeptide

United Therapeutics Europe Ltd

HIV Infections

phase 1 mab completed

1 trial
PA-824 1000 mg

BRIGHT MINDS BIOSCIENCES INC.

Tuberculosis

phase 1 small molecule completed

1 trial
PA-824 200mg

BRIGHT MINDS BIOSCIENCES INC.

Tuberculosis

phase 1 small molecule completed

1 trial
PAN-301-1

Sensei Biotherapeutics

Prostate Cancer

phase 1 mab completed

1 trial
PARP inhibitor BMN-673

BioMarin Pharmaceutical Australia Pty Ltd

Metastatic Cancer

phase 1 small molecule completed

1 trial
PAS-004 Capsules

Pasithea Therapeutics

RAS Mutation

phase 1 small molecule active

1 trial
PAS-004 Tablets

Pasithea Therapeutics

NF1 Mutation

phase 1 small molecule active

1 trial
PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

Chongqing Precision Biotech Co., Ltd

Non-small Cell Lung Cancer

phase 1 mab completed

1 trial
PBCAR19B

Chongqing Precision Biotech Co., Ltd

CD19 Expressing Malignancies

phase 1 gene therapy completed

1 trial
PBCAR269A

Chongqing Precision Biotech Co., Ltd

Relapsed/Refractory Multiple Myeloma

phase 1 gene therapy terminated

1 trial
PBGENE-HBV

Chongqing Precision Biotech Co., Ltd

HEPATITIS B CHRONIC

phase 1 mab active

1 trial
PC14586

PMV Pharmaceuticals

Healthy Volunteers

phase 1 small molecule completed

3 trials
PCS499

Processa Pharmaceuticals

Healthy

phase 1 small molecule completed

1 trial
PCS6422 and capecitabine

Processa Pharmaceuticals

Advanced Cancer

phase 1 small molecule completed

1 trial
PD-L1/IDO Peptide Vaccine

IO Biotech

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

phase 1 mab active

1 trial
PDR001

Novartis Pharmaceuticals

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

phase 1 mab completed

1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

Opicapone

Opioid Agonist

Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

Oral Fosmanogepix

Oral methylphenidate and Oral haloperidol

Original formulation EMB-001

Oshadi Oral Insulin

Osimertinib

Outpatient MST/OPTION-A

Oxcarbazepine

Oxcarbazepine (brand name vs generic drugs)

Oxidized regenerated cellulose(ORC)

OxyCODONE 5 mg Oral Tablet

Oxycodone

Oxycodone (OxyNorm®) Injection

Oxycodone (OxyNorm®) Injection

Oxycodone IN

Oxycodone Medication First

Oxycodone Tamper Resistant

Oxycodone and Midazolam

Oxymetazoline

Oxytocin

Oxytocin

Oxytocin lower does (24IU)

Oxytocin lower dose (24IU)

Oxytocin nasal spray

Oxytocine and migraine

P3C541b Lipopeptide

PA-824 1000 mg

PA-824 200mg

PAN-301-1

PARP inhibitor BMN-673

PAS-004 Capsules

PAS-004 Tablets

PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

PBCAR19B

PBCAR269A

PBGENE-HBV

PC14586

PCS499

PCS6422 and capecitabine

PD-L1/IDO Peptide Vaccine

PDR001

Frequently asked questions

Stay Ahead in Pharma